Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -93.44% is 79% below its 1-year average of -52.13%, near the low end of its 1-year range (-93.44%–-18.40%).
As of the fiscal period ended Tuesday, June 30, 2026. 58.70% below its 12-month average of -58.88%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -93.44%.
RETURN ON EQUITY (ROE)
-93.44%
RETURN ON EQUITY (ROE) AVG TTM
-58.88%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-58.70%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.44%
median of 550 covered companies
CURRENT VS SECTOR MEDIAN
-136.94%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$109.42M
Return on Equity (ROE)
-93.44%
TTM Avg
-58.88%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.05M
Return on Equity (ROE)
N/A
TTM Avg
148.53%
3Y Avg
-12.61%
5Y Avg
-408.56%
Market Cap
$108.64M
Return on Equity (ROE)
-80.97%
TTM Avg
-121.11%
3Y Avg
-93.50%
5Y Avg
-70.15%
Market Cap
$108.29M
Return on Equity (ROE)
-99.67%
TTM Avg
-40.73%
3Y Avg
98.81%
5Y Avg
13.93%
Market Cap
$107.75M
Return on Equity (ROE)
-87.45%
TTM Avg
455.42%
3Y Avg
120.34%
5Y Avg
63.42%
Market Cap
$111.14M
Return on Equity (ROE)
-5.10%
TTM Avg
-4.24%
3Y Avg
-6.16%
5Y Avg
0.09%
Market Cap
$107.44M
Return on Equity (ROE)
-44.29%
TTM Avg
-31.86%
3Y Avg
-53.29%
5Y Avg
-49.85%
Market Cap
$107.28M
Return on Equity (ROE)
-60.82%
TTM Avg
-19.88%
3Y Avg
-19.08%
5Y Avg
-15.27%
Market Cap
$113.30M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $109.42M | -93.44% | -58.88% | N/A | N/A |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | N/A | 148.53% | -12.61% | -408.56% |
| Apyx Medical Corporation (APYX)vs › | $108.64M | -80.97% | -121.11% | -93.50% | -70.15% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.29M | -99.67% | -40.73% | 98.81% | 13.93% |
| Immunic, Inc. (IMUX)vs › | $107.75M | -87.45% | 455.42% | 120.34% | 63.42% |
| BGM Group Ltd. (BGM)vs › | $111.14M | -5.10% | -4.24% | -6.16% | 0.09% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | -44.29% | -31.86% | -53.29% | -49.85% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.28M | -60.82% | -19.88% | -19.08% | -15.27% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | -0.05% | -43.47% | 9.13% | -18.50% |
| Definitive Healthcare Corp. (DH)vs › | $105.48M | -116.28% | -71.19% | -41.66% | -29.50% |
ROE
-93.4%
ROA
-85.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -93.44% |
| 2026-03-31 | -80.32% |
| 2025-12-31 | -54.01% |
| 2025-09-30 | -39.85% |
| 2025-06-30 | -26.76% |
| 2025-03-31 | -18.40% |
